New Ready-to-Use Caldolor is Designed to Help Address National Opioid Crisis.

 

We are very pleased to announce that the national launch of our FDA-approved Next Generation Caldolor product!

 

Cumberland Emerging Technologies Appoints a New Senior Executive

 

Cumberland Emerging Technologies, or CET, is a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, LaunchTN, and Winhealth Pharma Group. Its mission is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.

 

Orphan Drug Grant Funding for New Clinical Program!

 

We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.

 

Pages